Bailard Inc. Buys Shares of 16,113 Nkarta, Inc. (NASDAQ:NKTX)

Bailard Inc. purchased a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 16,113 shares of the company’s stock, valued at approximately $106,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Bourgeon Capital Management LLC bought a new stake in Nkarta during the 4th quarter worth approximately $30,000. Forefront Analytics LLC increased its holdings in shares of Nkarta by 282.5% in the third quarter. Forefront Analytics LLC now owns 39,657 shares of the company’s stock worth $55,000 after purchasing an additional 29,290 shares during the period. Bleakley Financial Group LLC bought a new position in shares of Nkarta in the fourth quarter worth $70,000. Simplicity Solutions LLC purchased a new stake in shares of Nkarta in the fourth quarter worth $70,000. Finally, SG Americas Securities LLC bought a new stake in Nkarta during the fourth quarter valued at $72,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Nkarta news, insider James Trager sold 4,143 shares of Nkarta stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $12.00, for a total transaction of $49,716.00. Following the completion of the sale, the insider now owns 149,415 shares of the company’s stock, valued at $1,792,980. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Simeon George bought 2,000,000 shares of the stock in a transaction dated Wednesday, March 27th. The stock was bought at an average price of $10.00 per share, with a total value of $20,000,000.00. Following the purchase, the director now owns 1,548,341 shares in the company, valued at approximately $15,483,410. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James Trager sold 4,143 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $12.00, for a total value of $49,716.00. Following the completion of the sale, the insider now directly owns 149,415 shares of the company’s stock, valued at approximately $1,792,980. The disclosure for this sale can be found here. Corporate insiders own 5.60% of the company’s stock.

Nkarta Stock Up 0.7 %

Shares of NKTX stock opened at $6.92 on Tuesday. The business has a 50-day moving average price of $10.35 and a two-hundred day moving average price of $7.07. Nkarta, Inc. has a 12-month low of $1.28 and a 12-month high of $16.24.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.05. On average, sell-side analysts forecast that Nkarta, Inc. will post -2.34 EPS for the current year.

Wall Street Analysts Forecast Growth

NKTX has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of Nkarta in a research note on Wednesday, April 10th. Raymond James restated an “outperform” rating and issued a $16.00 price objective (up from $13.00) on shares of Nkarta in a research report on Friday, March 22nd. HC Wainwright dropped their target price on shares of Nkarta from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, March 22nd. Canaccord Genuity Group boosted their price target on shares of Nkarta from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Finally, Mizuho lowered their price objective on shares of Nkarta from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nkarta presently has a consensus rating of “Buy” and a consensus target price of $17.83.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.